DEA Compliance Training: Controlled Substance Prescribing and Practitioner Requirements

$129.99

Why This Course is Important
Without this course, practitioners risk non-compliance with updated DEA rules, potential loss of prescribing privileges, audit failures, and exposure to significant legal and financial penalties.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment.

Key regulatory references include:

Course SKU
FR-26-1987-1

Description

Keep your practice compliant and prepared with this course on the DEA Final Rule implementing the SUPPORT Act and Restoring Hope for Mental Health and Well-Being Act. Learn about new practitioner training requirements, federal updates to prescribing and dispensing controlled substances, and best practices for documentation, recordkeeping, and audit readiness. This training is essential for any healthcare provider involved in prescribing or managing controlled substances under the latest DEA regulations.

In this course you will learn the following:
* Understand the legal authority and background of the Final Rule.
* Identify new practitioner training requirements and who they apply to.
* Implement the necessary steps to comply with the updated regulations.
* Recognize the legal and financial consequences of non-compliance.
* Apply the revised definitions and regulatory changes in daily practice.

Additional information

Federal Register Title

Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment. Document Number: 2026-11526

Course SKU

FR-26-1987-1

Why This Course Is Important

Without this course, practitioners risk non-compliance with updated DEA rules, potential loss of prescribing privileges, audit failures, and exposure to significant legal and financial penalties.